Cancer Network

🚨 New manuscript alert highlighting hereditary renal tumor syndromes after use with mTOR inhibitors. https://lnkd.in/dn7kYUWc #kicsm #cancer #oncology

Pregnancy-associated cancer rates increased by age, with women ages 15 to 19 at the lowest for PACs (5.3 cases per 100,000) and women ages 40 to 44 at the highest risk (63.5 cases per 100,000). https://lnkd.in/evXrjDb6 #cancer #oncology

Experts discussed the efficacy and durability of immunotherapy responses in patients with NSCLC. https://lnkd.in/e8CMGpZT #NSCLC #cancer #oncology

An ORR of 74% (95% CI, 48.8%-90.9%) among 19 evaluable patients was observed, with anti-tumor activity occurring across all dose levels. https://lnkd.in/eEzC9na9 #lcsm #cancer #oncology

A panel of experts focused on the use of dual immunotherapy options for patients with metastatic NSCLC without driver mutations. https://lnkd.in/esaWcJkX #NSCLC #cancer #oncology

The FDA has granted priority review to TLX101-CDx for use as a PET imaging agent for progressive or recurrent glioma. FDA https://lnkd.in/edkt9rgj #btsm #cancer #oncology

View the top 5 articles of the week: 1. https://lnkd.in/eHMha8Wn 2. https://lnkd.in/dQhNRPX7 3. https://lnkd.in/eTgD7ZNv 4. https://lnkd.in/ef43fi8E 5. https://lnkd.in/e9TWcqi6

Panelists discuss insights from the MARIPOSA study on first-line treatment options for EGFR-mutant metastatic NSCLC, highlighting the efficacy of amivantamab-lazertinib over osimertinib. https://lnkd.in/equ9DZX4 #NSCLC #cancer #oncoogy

Beth Faiman, CNP, PhD, outlines unique toxicities seen with other GPRC5D-targeted therapies in multiple myeloma. https://lnkd.in/e5Ccf_v7 #mmsm #cancer #oncology

Panelists discuss how colorectal cancer rates are increasing, particularly among younger adults, while highlighting the potential of ctDNA technology to improve early detection and treatment monitoring. https://lnkd.in/eQYAPdmH #gicsm #cancer #oncology